NCT03699475 - Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 27, 2018

Primary Completion Date

July 23, 2019

Study Completion Date

July 23, 2019

Conditions

Acute Myeloid LeukemiaMyelodysplastic Syndromes

Interventions

BIOLOGICAL

rivogenlecleucel

Biological: T cells transduced with caspase 9 safety switch

DRUG

rimiducid

administered to inactivate rivogenlecleucel in the event of GVHD

DRUG

Cyclophosphamide

GVHD prophylaxis

PROCEDURE

haplo-HSCT

treatment for disease

Trial Locations (2)

TriStar Bone Marrow Transplant, LLC, Nashville

Methodist Healthcare System of San Antonio Clinical Trials Office, San Antonio